1108 results about "Allergic reaction" patented technology

A fabric, in the form of a woven or knitted fabric or garment, including a flexible information infrastructure integrated within the fabric for collecting, processing, transmitting and receiving information concerning-but not limited to-a wearer of the fabric. The fabric allows a new way to customize information processing devices to "fit" the wearer by selecting and plugging in (or removing) chips/sensors from the fabric thus creating a wearable, mobile information infrastructure that can operate in a stand-alone or networked mode. The fabric can be provided with sensors for monitoring physical aspects of the wearer, for example body vital signs, such as heart rate, EKG, pulse, respiration rate, temperature, voice, and allergic reaction, as well as penetration of the fabric. The fabric consists of a base fabric ("comfort component"), and an information infrastructure component which can consist of a penetration detection component, or an electrical conductive component, or both. The preferred penetration detection component is a sheathed optical fiber. The information infrastructure component can include, in addition to an electrically conductive textile yarn, a sensor or a connector for a sensor. A process is provided for making an electrical interconnection between intersecting electrically conductive yarns. Furthermore, a process is established for sheathing the plastic optical fiber and protecting it.

The present invention utilizes carrier particles to present antigen peptides and proteins to the immune system in such a way as to induce antigen specific tolerance. The carrier particle is designed in order to trigger an immune tolerance effect. The invention is useful for treatment of immune related disorders such as autoimmune disease, transplant rejection and allergic reactions.

The present invention features methods to substantially increase the immunogenicity of a vaccine, preferably a DNA vaccine, and involves providing a mammal with a vaccine regimen, which includes an immunogen and Flt3L in combination with MIP-1α or MIP-3α. The methods of the present invention can be used for the prevention and treatment of various pathological states, including for example, cancer, microbial infections, autoimmune diseases, tissue rejection, and allergic reactions.

The present invention provides methods for treating, preventing or reducing the severity of allergic reactions. The present invention also provides methods for enhancing the efficacy and/or safety of an allergen-specific immunotherapy (SIT) regimen. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4Rα) antagonist such as an anti-IL-4Rα antibody.

Disclosed are cell preparations comprising multipotent adult stem cells and methods for using multipotent adult stem cells to treat autoimmune diseases, treat allergic responses, treat cancer, treat inflammatory diseases, treat fibrotic disorders, reduce inflammation and/or fibrosis, promote would healing, repair epithelial damage, and/or promote angiogenesis.

The invention provides a macromolecule bonding adriamycin medicine, a nanometer capsule and a preparation method thereof. The bonding medicine is bonded by a block copolymer of poly ethylene glycol-polylactic acid and adriamycin. Firstly, the block copolymer of poly ethylene glycol-polylactic acid is acquired by ring-opening polymerization of aliphatic cyclic esters with poly ethylene glycol, solvent and catalyst being in existence; then a carboxyl end group is transformed by a hydroxyl-terminated; and then with a condensing agent being in existence, the carboxyl end group carries out amidation reaction with the adriamycin; thus acquiring the macromolecule adriamycin bonding medicine. The bonding medicine has amphiphilic property, thus being able to self assembly to prepare the nanometer capsule with a core-shell structure in the water solution. The adriamycin is wrapped inside the capsule to play a role of isolation and protection, which overcomes the deficiencies of short circulation time in vivo, large dosage and severe allergic reaction existing in the current adriamycin preparation. In addition, the nanometer particles are expected to congregate in the blood circulation through the so-called 'enhanced infiltration and retention effect', so as to improve the targeting action of the adriamycin on the tumor location.

This invention provides a device and methods for the rapid detection and/or diagnosis and/or characterization of one or more allergies (e.g., causes IgE mediated allergic reaction (immediate hypersensitvity) in a mammal (e.g., a human or a non-human mammal). In certain embodiments, the device comprises a microcantilever array where different cantilevers comprising the array bear different antigens. Binding of IgE to the antigen on a cantilever causes bending of the cantilever which can be readily detected.

The invention discloses a muting sensitive lactalbumin hydrolysate and a preparation method thereof. The method mainly comprises the following steps: dissolving condensed whey protein in the water, then carrying out denaturation under high temperature, carrying out hydrolysis by using the protamex composed of alkali protease, papain and flavourzyme, treating the lactalbumin hydrating solution with desalinization and drying to obtain the lactalbumin hydrolysate of the invention. The lactalbumin hydrolysate of the invention has high suppression ratio of Beta-lactoglobulin and Alpha- lactalbumin, can reduce or eliminate cow milk allergic reaction; furthermore, the lactalbumin hydrolysate can also produce other active materials, thus also having the functions of promoting immunity, being easy to digest and absorb and reducing blood pressure; and the lactalbumin hydrolysate has high security and no side effect, bitter taste or other bad flavors.

The invention provides a composition including epinephrine nanoparticles and methods for therapeutic use of the composition in the treatment of conditions responsive to epinephrine such as a cardiac event or an allergic reaction, particularly anaphylaxis. The epinephrine nanoparticles can be incorporated into orally-disintegrating and fast-disintegrating tablet pharmaceutical formulations and can significantly increase the sublingual bioavailability of epinephrine, and thereby reduce the epinephrine dose required. Additionally, the invention provides methods for fabrication of stabilized epinephrine nanoparticles for use in the described compositions.

The invention discloses a natural pigment lipstick. The natural pigment lipstick is mainly prepared from, by weight, 3-7 parts of natural pigment, 15-20 parts of natural wax, 40-70 parts of natural oil, 2-5 parts of natural flavors and 1-3 parts of other natural functional additives. The lipstick uses natural plant extract juice as a pigment dye, other components do not contain any artificially synthesized compound, and the lipstick is non-toxic to a human body, can lubricate lip mucosa, does not produce allergic reaction, promotes blood circulation and body health and is wide in raw material source, simple and convenient to produce and low in cost.

The invention discloses a recombinant human collagen and an application thereof. An amino acid sequence of the protein is shown as SEQ ID NO. 3, the nucleotide sequence of the protein-coding gene is shown as SEQ ID NO. 1. The recombinant human collagen of the invention has very good hydrophilicity and stability, and the amino acid composition thereof is 100% identical to the corresponding amino acid sequence of the natural collagen, and the amount of expressed protein can account for about 25% of the total protein of the thalline, per milliliter of the bacteria liquid precipitate contains 0.25mg of the target protein, and the production cost is very low and the cycle is short. The prepared collagen is applied to the human body without immunological rejection and allergic reaction, and canbe widely applied to the biomedicine and cosmetics industries.

The invention discloses a sunscreen cosmetic composition and a method for preparing seaweed sunscreen components of the composition. The sunscreen cosmetic composition comprises the following components in percentage by weight based on the total weight of the composition: 0.01-10 percent of a porphyra umbilicalis extract, preferably 5 percent, 0.01-10 percent of a dunaliella salina extract, preferably 5 percent, 0.0001-1 percent of a haematococcus pluvialis extract, preferably 0.001 percent, 0.01-10 percent of seawater pearl powder, preferably 1 percent, and 0.01-10 percent of codium tomentosum extract, preferably 10 percent. According to the composition disclosed by the invention, the irritation and allergic reactions of organic sun-screening agents brought to the human body can be effectively reduced, the injured skin can be repaired during sun protection, and water is replenished to the skin. According to the preparation method disclosed by the invention, a wetting agent propylene glycol for cosmetics serves as an extraction solvent, the porphyra umbilicalis extract, dunaliella salina extract and haematococcus pluvialis extract are obtained under specific preparation conditions, and hazards of organic solvents for conventional extraction are avoided.

One embodiment of the present invention relates to systems and methods for detecting harmful and/or hazardous ingredients that may cause an allergic reaction, interfere with the effectiveness of a prescription drug, exacerbate symptoms associated with a chronic illness, and/or cause another undesired reaction.

The invention relates to a fragrant microcapsule type finishing agent which comprises the following constituents by mass percentage: 35-45 percent of fragrant nano microcapsule, 35-45 percent of thickening agent, 15-25 percent of adhesive and 1-5 percent of color paste, wherein the sum of the percentages of all the constituents is 100 percent. The invention also discloses a nano microcapsule type dry garment piece which has lasting fragrance more than 1 year, is sterile, has high safety, has no stimulation to the skin and no allergic response, and is suitable for fragrance finishing and storing of fabrics and ready-to-wear clothing made of cotton, wool, silk, linen and chemical fiber; and the fragrant nano microcapsule has good particle dispersivity on base cloth and is extremely easy to embed into the base cloth tissue structure.

This invention provides an altered kosher kappa casein polypeptide having at least one altered amino acid in a defined amino acid stretch. The defined amino acid stretch contributes to an allergic reaction induced by a kosher wild-type casein polypeptide in a human subject. Moreover, the defined amino acid stretch is expressed solely in kosher animals. The invention further provides an expression system for expressing the altered kosher casein polypeptide.

The present invention is directed to methods of treating diseases and disorders related to immune responses by administering one or more immunomodulatory compounds. In particular, the invention is directed to methods of stimulating and reducing immune responses, treating autoimmune conditions, treating allergic reactions and asthma, and preventing ischemic damage and asthma by administering one or more immunomodulatory compounds.

Information from a sensor that is local to a user is received. The information may indicate that the user has experienced a physiological event. The information is analyzed to determine whether the physiological event should be classified as an allergic reaction. If the physiological event should be classified as an allergic reaction, an action is taken such as particles currently present in the environment local to the user are collected.

The present invention discloses the use of the non-toxic cell-binding B subunit of CT (CTB), and holotoxin CT that is devoid of ADP-ribosylating activity, as adjuvants for enhancing transcutaneous immune response to a co-administered protein allergen. It was found that topical administration of CTB to mice induced serum antibody response against itself comparable to those evoked by CT, but was inefficient at promoting systemic antibody responses against an admixed prototype protein allergen. To the contrary co-administration of either CT or CTB with allergen led to vigorous antigen-specific T cell proliferative responses in lymph nodes draining the cutaneous site of administration and at distant systemic sites. Consistent with these observations, it was found that CTB selectively potentiated Th1-driven responses without affecting Th2-dependent responses. Cutaneously applied CT enhanced serum IgE responses to a co-administered allergen, while CTB partially suppressed epicutaneously induced IgE responses to the same allergen.

The invention discloses an acne removing and antiallergic cream which is prepared by mixing stearyl alcohol polyether-2, stearyl alcohol polyether-20, glycerin stearate, PEG (Polyethylene Glycol)-100 stearate, stearic acid, cetearyl alcohol, aloe oil, polydimethyl siloxane, isopropyl myristate, propyl p-hydroxybenzoate, methyl p-hydroxybenzene, tocopherol, azone, bisabolol, glycerol, xanthan gum, EDTA (Ethylene Diamine Tetraacetic Acid)-2Na, propylene glycol, ethanol, menthol, salicylic acid, a golden cypress extractive, a scutellaria baicalensis extractive, an India chinaberry leaf extractive, a spiraea ulmaria extractive, a bee milk extractive, an aloe leaf extractive, tea tree oil and sodium hydroxide. The acne removing and antiallergic cream disclosed by the invention can be used for removing acnes, promoting the facial blood circulation and skin cell regeneration, improving the skin tolerance and reducing or eliminating the allergic reaction of the skin; the allergic tolerance of the skin is improved, so that the cream is safe and effective; no any spices are added, so that allergens are greatly reduced.

The present invention provides unique, efficacious, inexpensive, safe, reliable, convenient, minimally bitter, skin protecting and penetrating, easy-to-administer base compositions and active agent-containing compositions, such as those including hydrocortisone, and related production and topical application methods, for treating the skin of mammals for a wide variety of different dermatologic conditions, disorders and diseases, such as inflammation, redness, cracking, insect bites, dryness, allergic reactions, trauma, irritant dermatitis, perleche, contact dermatitis, psoriasis, eczema, seborrheic dermatitis, acne excoriate, xerosis, eczema craquele, stasis dermatitis, disease related conditions and dryness from medications such as isotretinoin, acitretin and lipid lowering agents. This is effected by topically administering, or otherwise applying, effective amounts of the compositions thereto in forms that not only address the skin and mucosa of the mouth and lips, but also of the rest of the body and, in particular, areas where other topical balms containing hydrocortisone and other active ingredients have not been developed or marketed. Additionally, the flavoring addition to this product, and the base wherein the active ingredient(s) reside, affords a significantly better tasting, and less bitter, composition, thereby allowing a more pleasant experience and better compliance by patients. Larger sized stick formulation(s) allow for more applicability of the product, and more usefulness thereof, in various areas, and mucosal skin, of the body. The compositions include a unique formulation of FANCOL VB, Natunola Castor 1023, Finsolv TN, bees wax and, optionally, one or a plurality of plant or plant seed oils, fatty alcohols, fats and flavorings, in desirable weight percents thereof, in various forms, and preferably in the form of a solid roll-on stick present in a variety of sizes.

The invention discloses a plant compound gel for treating acne and a preparation method of the plant compound gel. The plant compound gel comprises the following natural plant components in parts by weight: 20-30 parts of radix sophorae flavescentis, 15-25 parts of cortex moutan, 10-20 parts of aloes, 10-20 parts of radix scutellariae and 15-25 parts of liquorice. The plant compound gel for treating acne provided by the invention contains natural plant active ingredients; the gel prepared according to a provided formula and the provided preparation method can be used with any common medicaments for acne treatment, and is applicable to any skins; the gel causes no allergic reactions, and has no toxic and side effects; by using the gel, medicaments can quickly penetrate into skins, thereby achieving the purpose of treating acne; the curative effect is exact, and the acne is difficult to relapse; the gel has functions of removing acne and eliminating cicatrices; and because of integrating active essences of natural plants, the gel can quickly achieve an antibacterial effect, detoxify and treat acne, and can improve the color of skins, restore the skin, and protect the skin.